Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivosidenib - Servier

Next Previous
X
Search
Drug Profile

Ivosidenib - Servier

Alternative Names: Tuoshuvo; AG-120; CS 3010; ivonib tablet; S-95031; TIBSOVO; Tosuvo; Tuoshuwo

Latest Information Update: 05 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Bristol-Myers Squibb; CStone Pharmaceuticals; HOVON Foundation; Servier; University of Pittsburgh Medical Center
  • Class Antineoplastics; Cyclobutanes; Nitriles; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Acute myeloid leukaemia; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Cholangiocarcinoma; Myelodysplastic syndromes
  • Phase III Chondrosarcoma
  • Phase II Glioma; Solid tumours

Most Recent Events

  • 09 Jul 2024 Phase-III clinical trials in Chondrosarcoma (Late-stage disease, Metastatic disease, Treatment-experienced) in Japan (PO) (NCT06127407)
  • 04 Jan 2024 Institut de Recherches Internationales Servier completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in the US and France (NCT02073994)
  • 21 Dec 2023 Servier acquires Ivosidenib from CStone Pharmaceuticals in China, Hong Kong, Macau, Taiwan and Singapore

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top